endo-hirsutism-avoid-insulin-lowering-drugs

name	endo-hirsutism-avoid-insulin-lowering-drugs
description	This skill advises against using insulin‑lowering drugs (e.g., metformin, thiazolidinediones) solely to treat hirsutism in premenopausal women. Apply when evaluating patient‑important hirsutism despite cosmetic measures or when insulin‑lowering therapy is considered for hyperandrogenism without other indications.

Avoid insulin‑lowering drugs solely for treating hirsutism

STEP 1 — Gather Information

Collect Ferriman‑Gallwey score, assessment of patient‑important hirsutism (distress prompting further treatment), cosmetic measures used, menstrual regularity, signs of hyperandrogenism (acne, alopecia, acanthosis nigricans), obesity, PCOS features, desire for fertility, contraception use, and VTE risk factors. → Proceed to rule in/out.

STEP 2 — Rule In / Rule Out

Is the hirsutism patient‑important despite cosmetic measures (e.g., shaving, plucking, waxing)?

• Yes → Proceed to classification.
• No → Consider cosmetic or direct hair removal only; insulin‑lowering drugs not indicated.

STEP 3 — Classify or Stratify

Assess for underlying endocrine disorder: menstrual irregularity, infertility, obesity, acanthosis nigricans, or elevated androgens on testing.

• Endocrine disorder present (e.g., PCOS, NCCAH) → Consider combined estrogen–progestin OC ± antiandrogen after 6 months if suboptimal.
• No endocrine disorder (idiopathic hirsutism) → Consider OC for cosmetic benefit or direct hair removal; lifestyle changes if PCOS/obese. → Proceed to decision.

STEP 4 — Decide

Avoid insulin‑lowering drugs as sole therapy for hirsutism.

• If OC appropriate and patient not seeking fertility → initiate combined OC (low‑dose EE, low‑risk progestin).
• If OC ineffective after ≥6 months → add antiandrogen (ensure contraception).
• If patient prefers non‑pharmacologic or has mild hirsutism without endocrine disorder → offer direct hair removal (laser/photoepilation or electrolysis).
  Document avoidance of insulin‑lowering drugs for hirsutism alone.

Clinical Guardrails / Mimics / Pitfalls

Do not prescribe metformin, thiazolidinediones, or other insulin‑lowering agents solely for hirsutism; avoid in women without diabetes or insulin resistance indication. Monitor for GI upset, lactic acidosis (metformin) or edema, weight gain (TZDs). Do not rely on insulin‑lowering drugs to treat hyperandrogenism unless managing PCOS metabolic features. Beware of missing adrenal neoplasm or Cushing’s syndrome when androgen levels are normal but clinical hyperandrogenism suggests otherwise.

Concrete Clinical Example

A 24‑year‑old woman presents with FG score 12, regular menses, mild facial hair distress despite shaving, no acne, not seeking pregnancy. She has patient‑important hirsutism despite cosmetic measures. Guideline recommends starting a combined OC; insulin‑lowering drug is not indicated for hirsutism alone.

Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Kathryn A. Martin et al., 2018, DOI:10.1210/jc.2018-00241